Sep 10, 2026
P21 for GLP-1 Discontinuation Anhedonia: Restoring Dopaminergic Signaling
P21, a CNTF-derived peptide, is being explored for anhedonia after GLP-1 discontinuation. Animal data suggest BDNF-mediated dopaminergic restoration
Read articleFIELD NOTES
Reading material for serious researchers.
Research notes, product guides, and insights from the Lakeshore Peptides team.
Sep 08, 2026
P21 vs Dihexa for Persistent Cognitive Fog After GLP-1 Discontinuation
P21 and Dihexa are experimental neurogenic compounds proposed for cognitive fog after GLP-1 discontinuation. This article compares their mechanisms
Read articleAug 27, 2026
Selank for Post-SSRI Emotional Blunting: Can This Anxiolytic Peptide Restore Affective Range Without Serotonergic Overactivation?
Post-SSRI emotional blunting leaves patients with flattened affect and anhedonia. Selank, a synthetic anxiolytic peptide, may restore affective range by
Read articleAug 20, 2026
Selank for GLP-1-Induced Anhedonia: Reward Sensitivity
GLP-1 receptor agonists have reshaped obesity care, but a subset of patients describe something that feels less like appetite suppression...
Read articleAug 18, 2026
Selank for GLP-1-Induced Cognitive Fog: A Peptide Rescue for Memory and Focus
GLP-1 receptor agonists have reshaped metabolic medicine, but their cognitive side effects remain poorly mapped. A subset of patients report...
Read articleAug 13, 2026
P21 and Selank: Stacking Neurogenic Peptides for Post-Concussion Cognitive Recovery
Post-concussion cognitive recovery is a slow, uneven climb. Two peptides, P21 and Selank, keep surfacing in preclinical and early clinical...
Read articleAug 11, 2026
P21 for GLP-1-Related Alcohol Craving Reduction in Veterans
Exploring the emerging link between GLP-1 agonists, alcohol craving reduction, and cognitive fog in veterans, and whether the peptide P21...
Read articleAug 06, 2026
P21 for GLP-1 Cognitive Fog: VA Trial Lessons
GLP-1 agonists can cause cognitive fog, but a 2023 VA trial on P21 for alcohol-related impairment offers clues. This peptide...
Read articleAug 04, 2026
P21 and GLP-1 Alcohol Trials: Cognitive Fog in Veterans
Veterans in GLP-1 alcohol trials sometimes face cognitive fog that hinders participation. This article explores P21, a synthetic peptide, as...
Read articleJul 30, 2026
P21 and Pinealon Synergy for Age-Related Cognitive Decline
P21 and Pinealon, two peptides under FDA review as a nootropic stack, target age-related cognitive decline through neurogenesis and epigenetic
Read articleJul 28, 2026
Selank for Performance Anxiety Under FDA Scrutiny
Selank, a synthetic tuftsin analogue, shows promise for anxiety without sedation, but FDA scrutiny and a lack of performance-specific trials...
Read articleJul 23, 2026
P21 for Chemobrain: Can This Peptide Reverse Chemotherapy-Induced Cognitive Decline?
Chemobrain affects up to 50% of cancer survivors, yet no approved treatment exists. The peptide P21 shows promise in animal...
Read articleJul 20, 2026
P21 vs. Cerebrolysin for Post-Concussion Cognitive Rehabilitation
Comparing P21 and Cerebrolysin for post-concussion cognitive recovery: a walk through the preclinical and clinical evidence, mechanisms, safety, and
Read article